The Vanguard Health Care Fund (Trades, Portfolio) increased its holdings of many stocks during the quarter. The eight largest are as follows.
The fund's Abbott Laboratories (ABT, Financial) stake was increased by 21.72% with an impact of 0.4% on the portfolio.
The health care company manufactures medical devices, blood glucose monitoring kits, nutritional health care products, diagnostic products and equipment and branded generic drugs.
GuruFocus gives the stock a profitability and growth rating of 4 out of 10. The return on equity (ROE) of 5.13% and return on assets (ROA) of 2.41% are outperforming 60% of the companies in the Global Medical Devices industry. Financial strength has a rating of 5 out of 10.
The largest shareholder among the guru is Vanguard with 1.24% of outstanding shares, followed by PRIMECAP Management (Trades, Portfolio) with 0.85%, Diamond Hill Capital (Trades, Portfolio) with 0.69%, Jeremy Grantham (Trades, Portfolio) with 0.29%, Mairs and Power (Trades, Portfolio) with 0.25%, Jim Simons (Trades, Portfolio) with 0.18% and Richard Pzena (Trades, Portfolio) with 0.17%.
The Baxter International Inc. (BAX, Financial) position was increased by 75.29% with an impact of 0.3% on the portfolio.
The company provides renal and hospital products such as infusion systems, parenteral nutrition therapies and biosurgery products.
GuruFocus gives the stock a profitability and growth rating of 5 out of 10. The ROE of 10.54% and ROA of 5.66% are outperforming 83% of the companies in the Global Medical Instruments and Supplies industry. Financial strength has a rating of 6 out of 10.
Daniel Loeb (Trades, Portfolio) is the largest shareholder of the company among the gurus with 7.54% of outstanding shares, followed by Bill Nygren (Trades, Portfolio) with 0.97%, Simons with 0.35%, Mairs and Power with 0.3%, Tweedy Browne (Trades, Portfolio) with 0.29%, Tweedy Browne Global Value with 0.19%, Joel Greenblatt (Trades, Portfolio) with 0.19% and Steven Cohen (Trades, Portfolio) with 0.12%.
The fund increased itsTeva Pharmaceutical Industries Ltd. (TEVA, Financial) stake by 36.25%. The transaction had an impact of 0.3% on the portfolio.
The pharmaceutical company develops, produces and markets generic and specialty medicines.
GuruFocus gives the stock a profitability and growth rating of 6 out of 10. The ROE of 0.24% and ROA of 0.43% are underperforming 69% of the companies in the Global Drug Manufacturers - Specialty and Generic industry. Financial strength has a rating of 4 out of 10. The cash-debt ratio of 0.03 is below the industry median of 2.05.
Barrow, Hanley, Mewhinney & Strauss is the largest shareholder of the company among the gurus with 2.93% of outstanding shares, followed by John Paulson (Trades, Portfolio) with 1.08%, Simons with 0.47%, David Tepper (Trades, Portfolio) with 0.21%, NWQ Managers (Trades, Portfolio) with 0.09%, Michael Price (Trades, Portfolio) with 0.07%, George Soros (Trades, Portfolio) with 0.06% and Julian Robertson (Trades, Portfolio) with 0.05%.
Vanguard's Becton, Dickinson and Co. (BDX, Financial) holding was increased by 53.40%, impacting the portfolio by 0.22%.
The health care company's products include medical devices, instrument systems and reagents used by health care institutions.
GuruFocus gives the stock a profitability and growth rating of 9 out of 10. The ROE of 16.90% and ROA of 5.20% are outperforming 58% of the companies in the Global Medical Instruments and Supplies industry. Financial strength has a rating of 5 out of 10. The cash-debt ratio of 0.09 is below the industry median of 1.55.
Another notable guru shareholder of the company is the T Rowe Price Equity Income Fund (Trades, Portfolio) with 0.67% of outstanding shares, followed by Grantham with 0.26%, Cohen with 0.24%, Pioneer Investments (Trades, Portfolio) with 0.12%, Mario Gabelli (Trades, Portfolio) with 0.05%, Robert Olstein (Trades, Portfolio) with 0.02% and Jeff Auxier (Trades, Portfolio) with 0.01%.
The Cardinal Health Inc. (CAH, Financial) stake was increased by 18.94%. The transaction had an impact of 0.2% on the portfolio.
The company provides services and products for hospital systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices.
GuruFocus gives the stock a profitability and growth rating of 5 out of 10. The ROE of 20.55% and ROA of 3.92% are outperforming 52% of the companies in the Global Medical Distribution industry. Financial strength has a rating of 6 out of 10. The cash-debt ratio of 0.25 is below the industry median of 0.60.
Barrow, Hanley, Mewhinney & Strauss is the largest shareholder of the company among the gurus with 6.55% of outstanding shares, followed by Pzena with 0.34%, Seth Klarman (Trades, Portfolio) with 0.33%, John Rogers (Trades, Portfolio) with 0.24%, Arnold Van Den Berg (Trades, Portfolio) with 0.03% and First Pacific Advisors (Trades, Portfolio) with 0.03%.
The fund increased its position in Eli Lilly and Co. (LLY) by 3.62% with an impact of -0.76% on the portfolio.
The pharmaceutical company produces drugs to treat a wide range of ailments, focusing on neuroscience, endocrinology, oncology and immunology.
GuruFocus gives the stock a profitability and growth rating of 6 out of 10. The ROE of 16.70% and ROA of 6.61% are outperforming 61% of the companies in the Global Drug Manufacturers - Major industry. Financial strength has a rating of 5 out of 10.
With 5.19% of outstanding shares. PRIMECAP Management is the company's largest guru shareholder, followed by Ken Fisher (Trades, Portfolio) with 0.27%, Simons with 0.27%, Sarah Ketterer (Trades, Portfolio) with 0.22%, Pioneer Investments with 0.12% and Cohen with 0.08%.
The Tesaro Inc. (TSRO, Financial) position was increased by 59.79%, expanding the portfolio 0.12%.
The biopharmaceutical company focuses on developing treatments for cancer.
GuruFocus gives the stock a profitability and growth rating of 4 out of 10. The ROE of -110.69% and ROA of -72.44% are underperforming 82% of the companies in the Global Biotechnology industry. Financial strength has a rating of 8 out of 10. The cash-debt ratio of 5 is below the industry median of 37.83.
Cohen is another notable guru shareholder of the company with 0.93% of outstanding shares, followed by Pioneer Investments with 0.2%, Leon Cooperman (Trades, Portfolio) with 0.05% and Paul Tudor Jones (Trades, Portfolio) with 0.01%.
The fund increased its Bristol-Myers Squibb Co. (BMY, Financial) stake by 1.61%, impacting the portfolio by just 0.1%.
The company develops and sells pharmaceutical and nutritional products.
GuruFocus gives the stock a profitability and growth rating of 6 out of 10. The ROE of 30.24% and ROA of 13.76% are outperforming 87% of the companies in the Global Drug Manufacturers - Major industry. Financial strength has a rating of 7 out of 10. The cash-debt ratio of 0.79 is above the industry median of 2.05.
Another notable guru shareholder is Dodge & Cox with 1.78% of outstanding shares, followed by Spiros Segalas (Trades, Portfolio) with 0.49%, Simons with 0.39%, the T Rowe Price Equity Income Fund with 0.29%, Manning & Napier Advisors Inc. with 0.12%, PRIMECAP Management with 0.11% and Jana Partners (Trades, Portfolio) with 0.04%.
Disclosure: I do not own any shares of any stocks mentioned in this article.